CoChat

Comparative Efficacy of Tirzepatide vs. Semaglutide in Reducing Body Weight in Humans: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Data

Open access
Aamir, Ahmad Bin, Latif, Rabia, Alqoofi, Jood Faisal, Almarzoq, Fatimah Abdulkarim, Fallatah, Joory Osamah, Hassan, Ghala Abdullah, Saab, Fatimah Abbas Abdullah Al Abu · 2025 · Journal of Clinical Medicine Research

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

Background: The aim of the study was to compare the effectiveness of tirzepatide versus semaglutide in producing weight loss. Methods: tests. A random-effect model was used to calculate pooled "mean differences" (MDs). Study quality was estimated by Newcastle-Ottawa Quality Assessment Scale (NOS) and Cochrane risk of bias (RoB) version 2 tool, and publication bias was estimated through forest plots and the Egger's test. Results: A total of two randomized controlled trials (RCTs) and five retrospective cohorts were included in this MA. MA results showed that compared with the semaglutide, tirzepatide could produce significantly greater weight loss (MD = 4.23; 95% confidence interval (CI): 3.22 - 5.25; P < 0.01). Subgroup analysis showed a dose- and duration-dependent significantly superior therapeutic effect of tirzepatide (> 10 mg dose: MD = 6.50, 95% CI: 5.93 - 7.08, P < 0.01 vs. ≤ 10 mg: MD = 3.89, 95% CI: 2.12 - 5.65, P < 0.01) (> 6 months duration: MD = 5.00, 95% CI: 3.48 - 6.52, P < 0.01 vs. ≤ 6 months: MD = 3.50, 95% CI: 2.24 - 4.75, P < 0.01). The supremacy of tirzepatide was maintained in both types of studies: RCTs and retrospective cohorts. No publication bias was found through forest plots visually or Egger's test (Egger's regression asymmetry test P value 0.94). Study quality estimated by NOS revealed the quality of each study as "good" (≥ 7 points) and that estimated by the Cochrane RoB tool revealed "low" RoB. Conclusion: The pooled analysis provides evidence that tirzepatide is better than semaglutide in reducing body weight, regardless of study design. A dose-response relationship exists, and the weight loss magnitude increases with the dose or duration of tirzepatide. The studies that provide this evidence are of high quality and have a low RoB.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.14740/jocmr6231

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 PRISMA flow diagram.
Figure 1 PRISMA flow diagram.CC BY-NC · PubMed Central
Figure 2 Forest plot of weight loss % mean differences in tirzepatide versus semaglutide interventions.
Figure 2 Forest plot of weight loss % mean differences in tirzepatide versus semaglutide interventions.CC BY-NC · PubMed Central
Figure 3 Forest plot of subgroup analysis based on tirzepatide dose.
Figure 3 Forest plot of subgroup analysis based on tirzepatide dose.CC BY-NC · PubMed Central
Figure 4 Forest plot of subgroup analysis based on tirzepatide duration.
Figure 4 Forest plot of subgroup analysis based on tirzepatide duration.CC BY-NC · PubMed Central
Figure 5 Forest plot of subgroup analysis based on study design.
Figure 5 Forest plot of subgroup analysis based on study design.CC BY-NC · PubMed Central
Figure 6 Sensitivity analysis of weight loss % mean differences in tirzepatide versus semaglutide interventions.
Figure 6 Sensitivity analysis of weight loss % mean differences in tirzepatide versus semaglutide interventions.CC BY-NC · PubMed Central
Figure 7 Funnel plots of studies reporting weight loss % induced by tirzepatide or semaglutide.
Figure 7 Funnel plots of studies reporting weight loss % induced by tirzepatide or semaglutide.CC BY-NC · PubMed Central
Figure 8 Risk of bias in all studies.
Figure 8 Risk of bias in all studies.CC BY-NC · PubMed Central
Figure 9 Risk of bias of individual studies.
Figure 9 Risk of bias of individual studies.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 21

Metadata

Authors
Aamir, A. B., Latif, R., Alqoofi, J. F., Almarzoq, F. A., Fallatah, J. O., Hassan, G. A., & Saab, F. A. A. A. A.
Affiliations
  • Punjab Medical College (PK)
  • Imam Abdulrahman Bin Faisal University (SA)
Corresponding author
Latif, Rabia
Venue
Journal of Clinical Medicine Research
Published
2025-05
Volume
17
Issue
5
Pages
285-296
ISSN
  • 1918-3003 (ISSN-L)
  • 1918-3011
OpenAlex
W4410798625
Cited by
19
References
26
Citations by year
2026: 17 · 2025: 2
FWCI
2.56
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Medicine Research (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Keywords
tirzepatide, semaglutide, weight loss, obesity, GLP-1 receptor agonists, GIP receptor agonist, dose-response relationship, treatment duration, drug efficacy comparison, real-world data, retrospective cohort, randomized controlled trials, publication bias, risk of bias, Newcastle-Ottawa Scale, Cochrane risk of bias tool, Egger's test

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.